Tenaya therapeutics receives fda fast track designation for tn-201

Tn-201 being developed for the potential treatment of mybpc3-associated hcm dosing in phase 1 clinical trial expected to commence in q3 2023 south san francisco, calif., may 02, 2023 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the u.s. food and drug administration (fda) has granted fast track designation for its gene therapy product candidate, tn-201, being developed for the treatment of myosin binding protein c3 (mybpc3)-associated hypertrophic cardiomyopathy (hcm).
TNYA Ratings Summary
TNYA Quant Ranking